RE:RE:Q3 - strong performanceAll good,
Plus, here's 2 important future catalysts to look for in the comming months:
1. Anticipated launch by Sundial Growers of cannabinoid products using CTX’s MMPE™ technology
2. CTX-101 outlicensing. CTX-101 is a topical corticosteroid for plaque psoriasis.
Crescita is responsible for formulation development / IP and providing its proprietary MMPE™
technology. Development is mainly funded by our partner Ferndale Laboratories and a leading U.S. Contract Research Organization. Economic benefits to be shared between partners upon out-licensing. In Q2-19, Crescita provided additional funding to support the advancement of the Phase 3 studies for CTX-101. Patents granted in the U.S. expiring in 2027. Applications pending in Australia, Canada, Europe, Mexico, New Zealand and the U.S. through 2036.